Comparative Pharmacology
Head-to-head clinical analysis: DEMECLOCYCLINE HYDROCHLORIDE versus DOXYCYCLINE HYCLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMECLOCYCLINE HYDROCHLORIDE versus DOXYCYCLINE HYCLATE.
DEMECLOCYCLINE HYDROCHLORIDE vs DOXYCYCLINE HYCLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by preventing aminoacyl-tRNA from attaching to the mRNA-ribosome complex.
Doxycycline hyclate is a bacteriostatic tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex. It also exhibits anti-inflammatory and anti-angiogenic properties.
150 mg orally every 6 hours or 300 mg orally every 12 hours. Maximum daily dose: 1200 mg.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg daily. For severe infections or certain indications, 100 mg every 12 hours.
None Documented
None Documented
10-17 hours; prolonged in renal impairment (up to 40–50 hours)
18-24 hours in patients with normal renal function; may increase to 24-48 hours in renal impairment; clinical context: allows once- or twice-daily dosing.
Renal: 40-50% unchanged; fecal/biliary: 10-15%
Approximately 40% excreted unchanged in urine via glomerular filtration; 20-30% eliminated in feces via biliary secretion and nonbiliary routes; the remainder is metabolized. Enterohepatic circulation contributes to prolonged half-life.
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic